A More Competitive Europe Through Smarter Health Decisions
Break The Bubble - an Incisive Health podcast
Break the Bubble
0.0 • 0 Ratings
🗓️ 31 March 2026
⏱️ 25 minutes
🧾️ Download transcript
Summary
Across Europe, a new chapter in Health Technology Assessment is taking shape.
Member States are now working together to assess the clinical value of new medicines through Joint Clinical Assessments under the EU HTA Regulation.
One year into its application, the conversation is moving from theory to reality. What does implementation actually look like? How are the first Joint Clinical Assessments being carried out? And why does this matter for patients, health systems and Europe’s innovation environment?
In this episode of Break the Bubble, Incisive Health Senior Counsel Hans Martens sits down with Maya Matthews, Head of the HTA Unit at DG SANTE.
Together, they explore how the first phase of the Regulation is taking shape, starting with oncology medicines and gene therapies. They discuss how Joint Clinical Assessments are aligned with EMA marketing authorizations, how patients and clinicians are now involved in shaping the assessment process, and how cooperation at EU level aims to reduce duplication while increasing transparency and quality.
What could this mean for innovation, for trust in decision-making and for access to new medicines across Europe?
Transcript
Click on a timestamp to play from that location
| 0:00.0 | How is healthcare changing in Europe? |
| 0:04.0 | How can we rethink partnerships between the public and private sectors? |
| 0:08.0 | How can patients be truly placed at the centre of EU healthcare policymaking? |
| 0:13.0 | These are some of the questions that break the bubble explores with the help of patients, |
| 0:19.0 | policymakers, industry representatives and healthcare professionals. |
| 0:24.0 | Above all, Break the Bubble is a space for experts to share visions, passions and solutions to |
| 0:29.8 | the most pressing EU healthcare policy debates. Welcome to Break the Bubble, an Insensitive Health |
| 0:35.8 | Podcast, available on Spotify and your favorite listening platforms. |
| 0:41.8 | Across Europe, a new chapter in health technology assessment is taking shape. |
| 0:46.8 | Member states are now working together to assess the clinical value of new medicines |
| 0:51.0 | through joint clinical assessments under the UHTA regulation. One year into its application, the conversation is moving from theory to reality. |
| 0:59.0 | What does implementation actually look like? |
| 1:02.0 | How are the first joint clinical assessments being carried out? |
| 1:05.0 | And why does this matter for patients, health systems and Europe's innovation environment? |
| 1:11.6 | In this episode of Break the Bubble, in Sizey Bell's Senior Council, Hans Martins, |
| 1:16.6 | sits down with Maya Matthews, head of the HTA unit at Digisante. |
| 1:21.6 | Together, they discuss how joint clinical assessments are aligned with EMA marketing authorizations, |
| 1:26.6 | how patients and |
| 1:28.1 | clinicians are now involved in shaping the assessment process and how cooperation at |
| 1:32.8 | you level aims to reduce application while increasing transparency and quality. |
| 1:38.6 | What could this mean for innovation, for trust in decision-making and for access to new |
| 1:43.0 | medicines across Europe. |
... |
Please login to see the full transcript.
Disclaimer: The podcast and artwork embedded on this page are from Break the Bubble, and are the property of its owner and not affiliated with or endorsed by Tapesearch.
Generated transcripts are the property of Break the Bubble and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.
Copyright © Tapesearch 2026.